RSV vaccines

The acceptability of maternal tetanus vaccines is generally high in LMICs. Acceptance of other maternal vaccines depends on the perception of safety to the infant. ^{Go to footnote 11}

Acceptability of RSV maternal vaccine is dependent on increasing the awareness of RSV. If key stakeholders are provided with reliable evidence to demonstrate the benefits of the RSVpre-F vaccine, it is likely to be acceptable. However, the cost of RSV vaccination is likely to influence how countries will prioritize its introduction relative to other vaccines or public health interventions. ^{Go to footnote 22}

For nirsevimab, acceptability to key stakeholders will depend on whether the price of the product is affordable in the country. Wide use of mAbs for passive immunization has never been implemented in LMICs. ^{Go to footnote 33}